Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Abbott wins USFDA...

    Abbott wins USFDA approval for blood plasma screening system Alinity s

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-18T09:15:41+05:30  |  Updated On 18 July 2019 9:15 AM IST
    Abbott wins USFDA approval for blood plasma screening system Alinity s

    Abbott's Alinity s is designed to screen blood and plasma more efficiently within a smaller space versus commercially available competitive systems.


    New Delhi: Abbott has announced that U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity s System. This new solution will bring the latest screening technology to U.S. blood and plasma centers.


    Alinity s is designed to screen blood and plasma more efficiently within a smaller space versus commercially available competitive systems. In a testing specialty that can require extensive hands-on time, the additional automation and flexibility of Alinity s will help blood and plasma centers improve productivity and maintain the highest levels of accuracy.


    Commenting on the approval, Louis Morrone, vice president, Transfusion Medicine, Abbott said, "Alinity s is a significant leap forward when it comes to speed, automation and efficiency for blood and plasma screening."


    "These elements are important to blood and plasma services of all sizes, supporting Abbott's overall mission to help people live longer, healthier lives by keeping the global blood and plasma supply safe, " Morrone added.


    Read Also: Abbott to increase production of lower-cost glucose monitors as diabetes soars


    Alinity s will help transform the blood and plasma screening process in terms of speed, capacity and "walk-away" time (i.e., when lab professionals are free to manage other responsibilities while the instrument processes samples) as a result of a number of new features:




    • Expands capacity to run up to 600 tests per hour.

    • Improves centers' ability to track all activities and actions associated with the testing and processing of each donation in accordance with regulatory requirements.

    • Increases walk-away time to a minimum of three hours while adding the ability to continuously access to refill/restock when convenient to the technician.

    • Equips laboratory professionals with the ability to continuously load and unload samples and supplies without pausing or stopping the system.

    • Features an intuitive software interface, menu design and sample loading layout, shared with other Alinity instruments, making it easy for lab technicians to learn and use.


    "In order to ensure a safe blood and plasma supply, we need access to the most advanced technologies to screen donations," said Rachel-Louise Beddard, M.D., senior vice president and chief medical officer, QualTex Laboratories. "Alinity s will help us transform the way we conduct screening, so we can do our jobs most efficiently, allowing us to get the life-saving blood and plasma products to people facing their most critical situations."

    AbbottAlinityAlinity sblood and plasma screeningblood screeningFDAFDA approvalLouis Morronepharmapharma newsplasma screeningQualTex LaboratoriesRachel-Louise BeddardUSFDAUSFDA approval

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok